- Home
- REPL vs ERAS Comparison
REPL vs ERAS Comparison
Compare REPL & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- ERAS
- Stock Information
- Founded
- REPL 2015
- ERAS 2018
- Country
- REPL United States
- ERAS United States
- Employees
- REPL N/A
- ERAS N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- REPL Health Care
- ERAS Health Care
- Exchange
- REPL Nasdaq
- ERAS Nasdaq
- Market Cap
- REPL 547.0M
- ERAS 439.7M
- IPO Year
- REPL 2018
- ERAS 2021
- Fundamental
- Price
- REPL $9.73
- ERAS $2.42
- Analyst Decision
- REPL Buy
- ERAS Buy
- Analyst Count
- REPL 9
- ERAS 6
- Target Price
- REPL $10.88
- ERAS $3.67
- AVG Volume (30 Days)
- REPL 8.7M
- ERAS 2.0M
- Earning Date
- REPL 11-07-2025
- ERAS 11-07-2025
- Dividend Yield
- REPL N/A
- ERAS N/A
- EPS Growth
- REPL N/A
- ERAS N/A
- EPS
- REPL N/A
- ERAS N/A
- Revenue
- REPL N/A
- ERAS N/A
- Revenue This Year
- REPL N/A
- ERAS N/A
- Revenue Next Year
- REPL N/A
- ERAS N/A
- P/E Ratio
- REPL N/A
- ERAS N/A
- Revenue Growth
- REPL N/A
- ERAS N/A
- 52 Week Low
- REPL $2.68
- ERAS $1.01
- 52 Week High
- REPL $17.00
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- REPL 76.27
- ERAS 60.58
- Support Level
- REPL $7.69
- ERAS $2.34
- Resistance Level
- REPL $10.85
- ERAS $2.54
- Average True Range (ATR)
- REPL 0.70
- ERAS 0.15
- MACD
- REPL 0.43
- ERAS -0.02
- Stochastic Oscillator
- REPL 89.86
- ERAS 68.42
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.